T Cell Receptor Mimic Antibodies

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cancer immunotherapy using antibodies is now part of the standard of care in treating various solid tumors and hematologic malignancies. The primary targets for these antibodies are large-cell-surface molecules that are expressed preferentially by tumor cells and that may also be expressed by normal cells. One approach to antibody therapy is to employ antibodies that target intracellular antigens that are presented by human leukocyte antigen (HLA) molecules on tumor cell surfaces. These peptide/HLA molecules are the natural targets for T cells. Antibodies that target peptide/HLA are known as T cell receptor mimic (TCRm) antibodies. Several such antibodies have been developed and tested preclinically in solid tumors and hematologic malignancies. In addition to using TCRm antibodies for conventional antibody-mediated tumor cell killing, these antibodies can be conjugated to toxins or engineered into chimeric antigen receptor T cells. Although TCRm antibodies are still in preclinical development, they are a promising tool for cancer immunotherapy.

Original languageEnglish (US)
Title of host publicationImmunotherapy in Translational Cancer Research
PublisherWiley-Blackwell
Pages186-200
Number of pages15
ISBN (Electronic)9781118684535
ISBN (Print)9781118123225
DOIs
StatePublished - Apr 13 2018

Keywords

  • Antibodies
  • Antigens
  • Cancer
  • Human leukocyte antigen (HLA)
  • Immunotherapy
  • Major histocompatibility (MHC)
  • Peptides
  • T cell receptor
  • T cell receptor-like

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'T Cell Receptor Mimic Antibodies'. Together they form a unique fingerprint.

Cite this